GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » Revenue per Share

Aclarion (Aclarion) Revenue per Share : $0.12 (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Aclarion Revenue per Share?

Aclarion's revenue per share for the three months ended in Mar. 2024 was $0.03. Aclarion's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.12.

Warning Sign:

Aclarion Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue Per Share Growth Rate of Aclarion was -23.70% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 7.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Aclarion's Revenue per Share or its related term are showing as below:

ACON' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 7.4   Med: 22.6   Max: 37.8
Current: 7.4

During the past 5 years, Aclarion's highest 3-Year average Revenue Per Share Growth Rate was 37.80% per year. The lowest was 7.40% per year. And the median was 22.60% per year.

ACON's 3-Year Revenue Growth Rate is ranked worse than
58.05% of 584 companies
in the Healthcare Providers & Services industry
Industry Median: 9.8 vs ACON: 7.40

Aclarion Revenue per Share Historical Data

The historical data trend for Aclarion's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion Revenue per Share Chart

Aclarion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
0.06 0.11 0.13 0.16 0.14

Aclarion Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.03 0.04 0.02 0.03

Competitive Comparison of Aclarion's Revenue per Share

For the Health Information Services subindustry, Aclarion's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclarion's PS Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Aclarion's PS Ratio distribution charts can be found below:

* The bar in red indicates where Aclarion's PS Ratio falls into.



Aclarion Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Aclarion's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=0.075/0.557
=0.13

Aclarion's Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as

Revenue Per Share (Q: Mar. 2024 )=Revenue (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=0.01/0.340
=0.03

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aclarion  (NAS:ACON) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Aclarion Revenue per Share Related Terms

Thank you for viewing the detailed overview of Aclarion's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclarion (Aclarion) Business Description

Traded in Other Exchanges
N/A
Address
8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Executives
John Paul Lorbiecki officer: Chief Financial Officer 238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness director, officer: Chief Executive Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond officer: Chief Strategy Officer 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch director 1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann director 130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann director, officer: Executive Chairman 8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks 10 percent owner 811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc 10 percent owner 7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc 10 percent owner 1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart director 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira director 951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal director C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404